Anticoagulation Management

Introduction to Reversal

• The American College of Critical Care Medicine and the European Society of Cardiology provide guidelines for the reversal of anticoagulation in patients with elevated INR, with a focus on reducing the risk of major bleeding and thrombosis 1, 2

Recommendations for Reversal

• For an INR of 15, a combination of four-factor prothrombin complex concentrate (PCC) and vitamin K is recommended over FFP alone due to faster reversal time and reduced mortality, with a strength of evidence level of high 1
• Four-factor PCC should be administered at 50 units/kg IV (maximum 5000 units) for rapid reversal, as recommended by the American College of Critical Care Medicine and the Critical Care Society 1, 3, 4
• Vitamin K should be administered at 10 mg IV (infuse slowly over 20-30 minutes) to sustain the reversal effect, as recommended by the American College of Critical Care Medicine and the European Society of Cardiology 1, 3, 5, 2
• Fresh frozen plasma (10-15 mL/kg) may be used if PCC is unavailable, with a strength of evidence level of moderate 1, 6

Monitoring and Adjunctive Therapy

• Repeat INR should be checked 15-60 minutes after PCC administration, and serial INR monitoring should be continued every 6-8 hours for 24-48 hours to ensure adequate reversal, as recommended by the American College of Critical Care Medicine 1
• If repeat INR remains ≥1.4 within 24-48 hours after initial PCC dosing, consider additional FFP, with a strength of evidence level of low 1
• Vitamin K is essential to sustain the reversal effect and should always be administered with PCC or FFP, as recommended by the American College of Critical Care Medicine and the European Society of Cardiology 1, 6, 2

Safety Considerations

• Thrombotic risk should be monitored, especially with repeated PCC dosing, with a strength of evidence level of moderate 1
• Patients with prosthetic heart valves should not receive intravenous vitamin K due to the risk of valve thrombosis if the INR falls rapidly, as recommended by the European Society of Cardiology 2
• Older adults may require more careful management due to increased bleeding risk, and the American Geriatrics Society recommends considering a lower target INR (2.0-2.5) when resuming therapy, with more frequent INR monitoring after resumption of therapy, with a strength of evidence level of high 7, 8

Special Populations

• Cancer patients have a higher risk of recurrent thrombosis, and low molecular weight heparin may be preferred over warfarin, as recommended by the American Heart Association and the American College of Cardiology, with a strength of evidence level of moderate 9, 10
• Warfarin is contraindicated in pregnancy, especially the first trimester, and low molecular weight heparin is preferred, as recommended by the American Heart Association and the American College of Cardiology, with a strength of evidence level of high 11, 9

Patient Education and Counseling

• Patients should be counseled on the importance of regular INR monitoring and the risks associated with elevated INR, as recommended by the American College of Cardiology/American Heart Association guidelines, with a strength of evidence level of high 12, 13
• Patients should be educated on the importance of medication adherence, maintaining consistent vitamin K intake, and reporting any changes in medications or health status, with a strength of evidence level of high 14

Dosage Recommendations

15, 1, 16, 17

Management of Bleeding

• If major bleeding occurs, administer vitamin K IV and consider fresh frozen plasma or prothrombin complex concentrate, as recommended by the European Society of Cardiology, with a strength of evidence level of high 18
• For an INR of 6.9 without active bleeding, administer 5 mg of oral vitamin K to safely reduce the INR within 24-48 hours, as recommended by the European Society of Cardiology, the American College of Chest Physicians, and the American College of Cardiology, with a strength of evidence level of moderate 19, 20
• For minor bleeding, hold warfarin and administer oral vitamin K 5-10 mg, monitoring INR every 6-12 hours until stabilized, as recommended by the European Society of Cardiology and the American College of Chest Physicians, with a strength of evidence level of low 19, 20
• For major or life-threatening bleeding, administer intravenous vitamin K 10 mg (infuse slowly) and four-factor prothrombin complex concentrate (PCC) at 35 U/kg, as recommended by the Critical Care Society, with a strength of evidence level of high 4